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Abstract
Background: Chronic Myeloid Leukaemia (CML) is caused by the BCR/ABL1 fusion gene. Both the presence and
the levels of BCR/ABL1 expression seem to be critical for CML progression from chronic phase (CP) to blast crisis
(BC). After the oncogenic translocation, the BCR/ABL1 gene is under the transcriptional control of BCR promoter but
the molecular mechanisms involved in the regulation of oncogene expression are mostly unknown.
Methods: A region of 1443bp of the functional BCR promoter was studied for transcription factor binding sites
through in-silico analysis and Chromatin Immunoprecipitation experiments. BCR and BCR/ABL1 expression levels
were analysed in CML cell lines after over-expression or silencing of MYC transcription factor. A luciferase reporter
assay was used to confirm its activity on BCR promoter.
Results: In the present study we demonstrate that MYC and its partner MAX bind to the BCR promoter, leading to
up-regulation of BCR and BCR/ABL1 at both transcriptional and protein levels. Accordingly, silencing of MYC expression
in various BCR/ABL1 positive cell lines causes significant downregulation of BCR and BCR/ABL1, which consequently
leads to decreased proliferation and induction of cell death.
Conclusions: Here we describe a regulatory pathway modulating BCR and BCR/ABL1 expression, showing that the BCR
promoter is under the transcriptional control of the MYC/MAX heterodimer. Since MYC is frequently over-expressed in
BC, this phenomenon could play a critical role in BCR/ABL1 up-regulation and blast aggressiveness acquired during
CML evolution.
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Background
Chronic Myeloid Leukaemia (CML) is a clonal myelo-
proliferative disorder caused by the constitutive tyrosine
kinase activity of the BCR/ABL1 fusion protein, the
product of the Philadelphia (Ph) chromosome, generated
from the t(9;22)(q34;q11) translocation [1]. If untreated,
CML progresses within 3-5 years from a mild and easy
to control form, called chronic phase (CP), to the ag-
gressive and incurable blast crisis (BC), the final phase
of this disease. In CP, BCR/ABL1 expression induces a
survival advantage but leukemic cells hold their capacity
to differentiate normally. Conversely BC, as any acute
leukemia, is marked by a complete differentiation block
and by the ensuing accumulation of blasts.
At the molecular level BC is a heterogeneous disease
[2, 3]. Regardless of the additionally secondary changes,
one common feature during the evolution from CP to
BC is a marked increase in BCR/ABL1 expression [3].
Progression to BC possibly occurs as a result of this
increase, which leads to the activation of several events
in primitive progenitor’s cell, such as genomic instabil-
ity, acquisition of resistance to apoptosis, and activation
of beta catenin in granulocyte-macrophage progenitors
resulting in the acquisition of self-renewal capacity [4–8].
Although the biological consequences of BCR/ABL1 up-
regulation have been intensively studied, the molecular
mechanisms responsible for this increase in expression are
mostly unexplored.* Correspondence: vera.magistroni@unimib.it†Equal contributors
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After the oncogenic translocation, the BCR/ABL1 gene
is under the transcriptional control of the BCR pro-
moter, which may play a critical role in controlling BCR/
ABL1 expression [9]; in fact a similar dysregulation of
both BCR and BCR/ABL1 gene transcription is evident
in BC [10]. Limited efforts have been devoted until now
to the characterization of BCR promoter: according to
Shah et al. [9] a functional promoter is localized in a
region of 1Kb at the 5′ of the BCR exon 1 coding
sequence. Recent results from Marega et al confirmed the
importance of this region for BCR basal transcriptional
level: this study showed that the sequence comprised
between -1443 and -1202 bp from the ATG site is critical
to achieve a high level of BCR promoter activity [10].
MYC is a transcription factor belonging to the basic-
helix-loop-helix-leucine zipper (bHLH-LZ) family [11].
It forms heterodimers with the bHLH-LZ partner MAX,
subsequently binding to a core DNA consensus region.
Assembly of MYC/MAX heterodimer and DNA-binding
seems to be crucial for the mitogenic, oncogenic and
antiapoptotic functions of MYC [12, 13]. MYC is acti-
vated in various cancers through different genomic
events including chromosomal translocation or gene
amplification [14–18]. MYC protein has been shown to
play a role in BCR/ABL1 mediated transformation,
mainly by acting as a cooperative oncogene with the
fusion protein [19–21]. Furthermore, BCR/ABL1 can
induce MYC activity through distinct mechanisms: by
regulating MYC expression through PI3K, JAK2 path-
ways and the E2F1 transcription factor [22–24], by inhi-
biting MYC proteasome-dependent degradation through
activated JAK2 [25] and by regulating MYC mRNA
translation by enhancing HNRPK translation-regulation
activity [26]. MYC is also a known BCR binding partner
[27] and higher BCR levels can decrease MYC protein
levels, thus suggesting that BCR monoallelic disruption
through BCR/ABL1 translocation may contribute to
MYC protein stability in CML. Interestingly, MYC
expression is normal in CP-CML, but is frequently
up-regulated in BC through chromosome 8 amplification
or over-expression [28]. Recently, Lucas CM et al. [29]
showed that pharmacological inhibition of MYC reduces
BCR/ABL1 tyrosine kinase activity and its expression
level. These data suggest a causative role for MYC in the
regulation of BCR/ABL1 expression, but they did not
identify the molecular basis of this phenomenon. In the
present study we demonstrate for the first time that
MYC/MAX heterocomplex binds to the BCR promoter
at four specific binding sites, leading to up-regulation of
BCR and BCR/ABL1 at both transcriptional and protein
levels in CML cell lines. Accordingly, silencing of MYC
expression in various BCR/ABL1 positive cell lines
causes significant downregulation of BCR and BCR/
ABL1, decreases proliferation rate and induces cell death
in CML cells. Since MYC is frequently over-expressed in
BC, this phenomenon could be responsible for the BCR/
ABL1 up-regulation and blast aggressiveness showed
during CML evolution.
Results
In-silico identification of MYC and MAX transcription
factors binding sites on BCR promoter
To identify the transcription factors directly involved in
BCR promoter regulation, we studied a region of
1443bp upstream of the human BCR gene coding se-
quence (Breakpoint Cluster Region; NC_000022.11).
According to Marega et al. [10] and to previous studies
[9, 30], this region contains critical elements for the
regulation of BCR transcription. Through in-silico ana-
lysis we identified distinct putative binding sites for
several transcription factors [10]. Criteria for selecting
the transcription factors (TFs) were: 1) TFs binds to a
DNase protected area of BCR promoter [9]; 2) TFs have
role in hematopoiesis or differentiation of hematopoietic
progenitors. Based on the DNA binding matrix shown in
Fig. 1a we found four highly relevant MYC/MAX binding
sites (PBS) located at PBS1 (-1354 bp to -1364bp), PBS2
(-1279 to -1269 bp), PBS3 (- 813 bp to -803 bp) and PBS4
(-767 bp to -757 bp) (Fig. 1b).
MYC and MAX bind to BCR promoter
To assess the validity of the in-silico prediction, we per-
formed Chromatin Immunoprecipitation analyses (ChIP)
on the BCR/ABL1-positive K562 cell line, which showed
a highly significant enrichment for BCR promoter on
the previously identified regions after MYC and MAX
immunoprecipitations compared to the negative control
(MYC: MYC_R1 0.0048 ± 0.0002, IgG_R1 0.001 ± 0.00009;
MYC_R2 0.01 ± 0.0005, IgG_R2 0.001 ± 0.0002; MAX:
MAX_R1 0.01 ± 0.0009, IgG_R1 0.0035 ± 0.0001, MAX_R2
0.02 ± 0.001, IgG_R2 0.0029 ± 0.0002; MYC_R1 vs IgG_R1,
p < 0.0001; MYC_R2 vs IgG_R2 p < 0.0001; MAX_R1 vs
IgG_R1 p < 0.0001; MAX_R2 vs IgG_R2 p < 0.0001)
(Fig. 1c and d). The Nucleophosmin (NPM1) [31] and the
methionyl-tRNA synthetase (MARS) [32] promoters
were used as positive controls for MYC and MAX binding,
respectively (MYC_NPM1 0.01 ± 0.0008, IgG_NPM1
0.00076 ± 0.00009; MAX_MARS 0.02 ± 0.0006, IgG_MARS
0.0017 ± 0.0002, MYC_NPM1 vs IgG_NPM1 p < 0.0001;
MAX_MARS vs IgG_MARS p < 0.0001).
Overexpression of MYC and MAX causes BCR and BCR/
ABL1 up-regulation in CML cell lines
To investigate the role of MYC and MAX binding on
BCR promoter, we overexpressed MYC, MAX and
MYC/MAX in the BCR/ABL1-positive K562 cell line
(Fig. 2a-c) and we assessed the effect of MYC/MAX
overexpression on BCR and BCR/ABL1 at mRNA and
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Fig. 1 (See legend on next page.)
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protein levels. We found that, both MYC and MYC/
MAX over-expression significantly upregulate BCR/ABL1
compared to control cells (Empty), as assessed by Real-
Time quantitative PCR (RT-qPCR) (MYC_BCR/ABL1 fold
induction: 2.27 ± 0.48, p = 0.01; MYC/MAX_BCR/ABL1
fold induction: 2.55 ± 0.34, p = 0.002) and western blot
analysis. A similar trend is also shown for BCR levels
(MYC_BCR fold induction: 1.46 ± 1.34, p = 0.62; MYC/
MAX_BCR fold induction: 2.17 ± 0.92, p = 0.14) (Fig. 2d-f).
Interestingly, over-expression of MAX alone is not able to
induce significant up-regulation of both BCR and BCR/
ABL1 (MAX_BCR fold induction: 0.83 ± 0.79, p = 0.78;
MAX_BCR/ABL1 fold induction: 1.30 ± 0.32, p = 0.2).
Silencing of MYC causes a significant decrease in BCR and
BCR/ABL1 levels and induces cell death in CML cell lines
To further test the effect of MYC on BCR and BCR/
ABL1 expression, we generated a lentiviral silencing
model targeting MYC expression in the K562 cell line.
The effect of the lentiviral silencing was assessed by
Fig. 2 Effect of MYC and MAX on BCR and BCR/ABL1 expression in K562 cell line. MYC (a,c) and MAX (b,c) over-expression in K562 cells stably
transfected with MAX, MYC, or pcDNA3 empty vector (Empty) or MYC/MAX (MYC::MAX), as evidenced by RTq-PCR (a,b) and Western Blot from
total lysates (c). RT-qPCR (d,e) and Western Blot (f) show BCR and BCR/ABL1 expression levels in K562 transfectants. Actin was used as loading
control. The RTq-PCR data shown in (d,e) represent the means ± SD (standard deviation) of three independent experiments. Data are represented
as mRNA fold change compared to the Empty sample
(See figure on previous page.)
Fig. 1 MYC and MAX binding at BCR promoter. (a) Schematic representation of 11-nucleotide position frequency matrix for MYC/MAX binding
(MA0059.1) as obtained from Jaspar core database. The height of the nucleotides of the “sequence logo” represents the conservation of the
nucleotides measured in bits (binary digit) (b) Nucleotide sequence of the BCR promoter region analyzed in this study. Lowercase nucleotides
represent the regions cloned in the pGL3 vector. Consensus regions for MYC/MAX binding are underlined. The regions amplified in Chromatin
Immunoprecipitation (ChIP) analysis are highlighted in orange (Region 1, R1) and yellow (Region 2, R2). The BCR transcriptional starting site,
according to NM_021574.2 and NM_004327.3, is highlighted as a red asterisk. (c, d) ChIP results for MYC and MAX binding at region1 (R1) and
region 2 (R2) and for MYC and MAX positive controls. The RTq-PCR data represent the means ± SD (standard deviation) of two independent
experiments. An IgG antibody was used as negative control. Signals are normalized to the Input DNA. *** = p < 0.0001
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mean of RT-qPCR and western blot on BCR/ABL1 and
BCR. MYC silencing significantly reduces BCR/ABL1
levels in K562 cells compared to the negative control, as
determined by RT-qPCR (BCR/ABL1 fold change: 0.66 ±
0.08, p = 0.03) and western blot (Fig. 3a, c and d). A similar
trend is observed for BCR level (BCR fold change: 0.8 ±
0.13, p = 0.12) (Fig. 3b). The test if the effect of MYC
down-modulation on BCR and BCR/ABL1 expression was
limited to the K562 cells or was evident on other BCR/
ABL1 positive cell lines, we generated MYC silencing
models in KCL-22 and LAMA-84, showing significant
down-regulation of both BCR and BCR/ABL1 compared
to their negative controls at the mRNA (BCR fold change:
KCL-22 0.49 ± 0.07, p = 0.013; LAMA-84 0.07 ± 0.03,
p = 0.0003. BCR/ABL1 fold change: KCL-22 0.58 ± 0.02,
p = 0.0007; LAMA-84 0.38 ± 0.006, p < 0.0001) and pro-
tein levels (Fig. 3b-d).
Finally, given the recognized role of MYC in v-ABL1
transforming potential [21], we confirmed that MYC
silencing in CML cell lines resulted, together with BCR
and BCR/ABL1 down-modulation, in a highly significant
growth arrest (p < 0.0001) (Fig. 4b and d) and in induc-
tion of cell death (Fig. 4a, c and e).
MYC controls the activity of BCR promoter
To define if the modulation of BCR and BCR/ABL1
expression by MYC is a direct consequence of MYC
activity on the four binding sites identified on BCR
promoter, we set-up a luciferase reporter assay on 293T
cells (Fig. 5). We created BCR promoter constructs as
follows: 1) Full_BCR: 1443 bp upstream of the BCR
coding starting site comprising all four MYC/MAX
binding sites, 2) Full_BCRΔ34: 1443 bp upstream of the
BCR coding starting site with deletion of a region com-
prising the third and fourth MYC/MAX binding sites, 3)
1200_BCR: 1204 bp upstream of the BCR coding start-
ing site with only the third and fourth MYC/MAX
binding sites; 4) 1200_BCRΔ34: 1204 bp upstream of the
ATG with no MYC/MAX binding sites (Fig. 5c). In
order to assess the effect of MYC/MAX on BCR pro-
moter we tested the activity of the luciferase reporter
assay in presence of MYC expression and in a lentiviral
MYC silencing model (Fig. 5a and b), showing that MYC
silencing significantly decreases BCR promoter activity
in all of the constructs analysed (p < 0.0001) (Fig. 5c).
Notably, deletion of PBS1 and PBS2 (1200_BCR con-
struct) and/or deletion of PBS3 and PBS4 (Full_BCRΔ34
Fig. 3 MYC silencing causes downregulation of BCR and BCR/ABL1 expression. The BCR/ABL1-positive cell lines K562, KCL-22 and LAMA-84
were infected with lentiviruses expressing scrambled shRNA (negative control: shNC) or MYC shRNA (shMYC). (a-c) RT-qPCR for MYC, BCR and
BCR/ABL1 levels. Data are represented as mRNA fold change compared to the shNC sample. ***: p < 0.001, **: p < 0.01,*: p < 0.05. Signals are
representative of two independent experiments (d) Western Blot analysis of total cell lysates. Actin was used as loading control
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and 1200_BCRΔ34 constructs) dramatically decreases
the overall promoter strength, even in presence of MYC
expression, therefore confirming the critical role of
these region in controlling BCR promoter activity. In
line with these findings, the loss of PBS1 to 4 almost
completely abrogates BCR promoter activity, suggesting
that they represent core controllers of BCR promoter
regulation. Interestingly, the deletion of PBS3 and PBS4
(Full_BCRΔ34) induces a greater down-modulation of
luciferase activity compared to PBS1 and PBS2 deletion
(1200_BCR) (Full_BCR shNC 6.11 ± 0.11, Full_BCRΔ34
shNC 1.86 ± 0.14, 1200_BCR shNC 3.92 ± 0.07) (Fig. 5c),
Fig. 4 Biological role of MYC silencing in CML cell lines. Immunoblots for MYC, PARP-1 and Actin in LAMA-84 (a) and KCL-22 (c) cell lines encoding
MYC-shRNA (shMYC) or the control shRNA (shNC). The PARP-1 antibody recognizes total (116kDA) and cleaved PARP-1 (85/25kDa). Cell viability of
the same cells (b,d) was determined by the MTS assay. Values represent the mean normalized percentage of survival compared to control cells
(n = 5 wells; ± SD). (***: p < 0.001). (e) Flow cytometry analysis of propidium iodide (PI) stained KCL-22 cells after 72h of MYC silencing
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in accordance with the greater ChIp enrichment observed
for MYC binding at Region 2(R2) compared to Region
1(R1) (Fig. 1c). These results confirm the role of the four
MYC binding sites (PBS1-4) in BCR promoter regulation,
also suggesting a prominent role for PBS3 and PBS4.
Discussion
In CML cells, after the t(9;22)(q34;q11) translocation
and the formation of the Philadelphia chromosome, the
BCR promoter drives the production of the BCR/ABL1
mRNA [9]. This oncogenic product is necessary and
sufficient for the malignant transformation of hema-
topoietic cells in-vitro and in-vivo [33] and during
CML progression the BCR/ABL1 oncogene persist and
its level increases [34–36]. The enhanced BCR/ABL1
activity characteristic of BC phase, seems to influence
proliferation, survival, genetic instability and differenti-
ation of myeloid progenitors [3, 5–8].
A number of previous reports suggested the involvement
of MYC in the clonal evolution of CML. MYC protein
collaborate with BCR/ABL1 to induce blastic transform-
ation, as assessed by the therapeutic efficacy of a silencing
combination therapy for MYC and BCR/ABL1 of primary
CML cells in SCID mice [37]. Interestingly, MYC is also
often upregulated in BC through chromosome 8 trisomy
or gene amplification [19, 20, 28, 38]. It has also been
suggested that BCR can decrease MYC activity by regu-
lating its stability at protein level [27]: BCR disruption
during BCR/ABL1 translocation can thus contribute to
CML transformation leading to MYC upregulation.
MYC levels are also controlled by BCR/ABL1 oncopro-
tein at transcriptional and protein levels [22–26]. The
role of MYC activity in blastic transformation is also
strengthen by the fact that MYC is a known beta-
catenin target gene, which has been shown to be acti-
vated in BC patients [4, 39].
According to previous reports, BCR is physiologically
down-regulated upon myeloid maturation from hema-
topoietic stem cells (HSCs) to common myeloid progen-
itors (CMPs) and granulocyte-macrophage progenitors
Fig. 5 PBS1-4 are critical for BCR promoter regulation. 293 cells were infected with lentiviruses expressing scrambled shRNA (negative control:
shNC) or MYC shRNA (shMYC). (a,b) RT-qPCR and Western Blot analyses assessing MYC expression levels. (c) Luciferase assay on 293 infected cells.
The four MYC/MAX binding sites are numbered in the figure (1-4). The graph shows the relative luciferase values as assessed after normalization
with Renilla Luciferase signal. Values reported in the graph represent the average of three separate experiments. *** = p < 0.0001
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(GMPs) and this mechanism is conserved in healthy
donors and in CP-CML [39]. Conversely, in BC this
regulation is impaired for both BCR/ABL1 and BCR,
which suggests the presence of ‘in trans’ deregulated
transcription of both BCR and BCR/ABL1 promoters
associated with CML progression [10]. A direct effect of
MYC leading to an increase in BCR/ABL1 levels has
recently been suggested [29], but the molecular mechan-
ism responsible for this phenomenon has not been
clarified.
We showed here that MYC/MAX heterodimer can bind
to BCR promoter at four specific loci (Fig. 1), thus regulat-
ing BCR and BCR/ABL1 expression in several CML cell
line models (Figs. 2 and 3). By using a luciferase reporter
assay we confirmed that MYC can modulate BCR and
BCR/ABL1 expression by directly controlling BCR pro-
moter activity (Fig. 5). Interestingly, when PBS3 and PBS4
were deleted from the BCR promoter construct (Full_BCR
Δ3,4; 1200_BCR Δ3,4), a dramatic decrease in luciferase
activity was observed when compared to all the other con-
structs, thus suggesting a critical role of these two regions
in the regulation of BCR promoter activity (Fig. 5).
Our results show the existence of a positive feedback
mechanism between the fusion protein BCR/ABL1 and
the MYC transcription factor. BCR/ABL1 expression
increases MYC activity which, in turn, is able to
up-regulate BCR/ABL1 levels through direct binding on
BCR promoter.
Conclusions
We present here the first description of a new pathway
which places BCR and BCR/ABL1 under the transcriptional
control of the MYC/MAX heterodimer. Our findings con-
firm the oncogenic role of MYC in CML pathogenesis, sug-
gesting a causal relationship with the increased BCR/ABL1
levels observed during CML progression. Further analyses




The BCR/ABL-positive CML cell lines K562, LAMA-84
and KCL-22 (DSMZ, Braunschweig, Germany) were cul-
tured in RPMI-1640 medium supplemented with 10 % FBS,
2mM L-glutamine, 100 U/ml penicillin G, 80 μg/ml genta-
micin and 20 mM HEPES in a 5 % CO2 incubator at 37°C.
The 293-FT (R700-07, Life Technologies-Thermo Fisher
Scientific, Waltham, MA USA) and the 293 cell lines
(R750-07, Life Technologies-Thermo Fisher Scientific) were
maintained following manufacturer instructions.
In silico analysis
To define the transcription factors involved in the
regulation of BCR expression, in silico analysis of BCR
promoter (1443bp from the ATG site) was done using
the open access Jaspar core database [40], available on
http://jaspar.genereg.net/. The putative binding sites for
transcription factors were generated from the distribu-
tions of bases at each position of all the transcription
factors frequency matrices available in the JASPAR data-
base. The putative binding sites with a relative profile
threshold ≥ 80 % and a binding score >8 were selected
for subsequent analyses.
Chromatin Immunoprecipitation (ChIP)
Chromatin immunoprecipitation was performed on K562
cells as previously reported [41]. Briefly, proteins were
cross-linked with 0.4 % formaldehyde and cells lysed.
Chromatin was fragmented with a Bioruptor sonicator
system (Diagenode, SA, USA) and subsequently immuno-
precipitated with anti-MYC[N-262] (SC-764X, Santa Cruz
Biotechnology Inc., Texas, USA), anti-MAX[C-17]
(SC-197X, Santa Cruz Biotechnology) or non-specific IgG
antibodies. After purification, immunoprecipitated DNA
was amplified with RT-qPCR as described in [42]. Results
were visualized after separating PCR products by agarose
gel with ethidium bromide staining. Primers used for the
quantitative RT-PCR were: BCR-MycMax-Fw 5′GGGAA
GTTCTGAGTCAGGTCG3′ and BCR-MycMax-Rw 5′TG
AGTAACCAATGCCAGCACCC3′ for the amplification
of a region including PBS1 and PBS2; 2BCR-MycMax-
Fw 5′GAGGACTGCTGCGAGTTCTGCC3′ and 2BCR-
MycMax-Rw 5′-GACTCCCTGGTCCATAAAGACC3′
for the amplification of a region including PBS3 and PBS4;
NPM1_MycFw 5′CTCGTGAGCCAGGGATGCT3′ and
NPM1_MycRw 5′CCCTAGTGCTACCAGCCTCTTAAC3′
for the amplification of MYC binding positive control;
MARS-MaxFw 5′AAGTGCGACTTGCCCTAAAA3′ and
MARS-MaxRw 5′CCATGCAGCTGGGACTACA3′ for the
amplification of MAX binding positive control [31, 32].
Real-time quantitative PCR (RT-qPCR)
Total RNA was extracted by Trizol reagent following
standard procedures (Life Technologies). cDNA was
synthesized from 1μg of total RNA, using Reverse Tran-
scription Reagents (Applied Biosystems-Life Technolo-
gies). The total RNA obtained from transfectant cells
were pretreated with DNAseI (Life Technologies) to
avoid contamination from genomic DNA. RT-qPCR was
performed using TaqMan® Brilliant II QPCR Master Mix
(Agilent technologies, Santa Clara, CA, USA) for
TaqMan assays or with Brilliant III Ultra-fast SYBR
Green QPCR Master Mix (Agilent technologies) for
SYBR Green assays on a Stratagene-MX3005P (Agilent
technologies) under standard conditions. All the RT-
qPCR experiments were performed in triplicate. The
housekeeping gene β-glucronidase (GUSB) was used as
an internal reference as assessed by [43]. For MYC and
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MAX expression analysis we used TaqMan® Gene Expres-
sion Assays(Applied Biosystems-Life Technologies) consist-
ing of a pair of unlabeled PCR primers and a TaqMan®
probe. TaqMan RT-qPCR was performed according to the
manufacturer’s specifications. The assay identification
numbers were as follows: MYC-Hs00153408_m1, MAX-
Hs01105524_g1. BCR, BCR/ABL and GUSb RT-qPCR
primers/probes have been previously described [10].
Western blot analysis
Western Blot was performed as previously described
[42] using the following antibodies: rabbit anti-MAX
[C-17] (sc-197X)(Santa Cruz Biotechnology), mouse anti
c-MYC[9E10] (sc-40)(Santa Cruz Biotechnology), rabbit
anti-c-ABL[K-12] (sc-131)(Santa Cruz Biotechnology),
rabbit anti PARP-1[E102] (ab32138)(Abcam, Cambridge,
UK) and anti-ACTIN (A2066)(Sigma-Aldrich, St Louis,
MO, USA).
BCR promoter constructs and site-direct mutagenesis
pGL3_BCR promoter constructs were obtained as in
[10]. Briefly, a region of 1443bp of the human BCR gene
(NC_000022.11) from the first nucleotide upstream the
ATG starting site was inserted in the pGL3 vector
(Fig. 1b). Mutations in the BCR promoter at the MYC:
MAX binding sites were introduced by the following
protocol. Specific primers were designed and used to
mutagenize the pGL3-Full_BCR and the pGL3-1200_BCR
plasmids by using the Pfu Ultra High Fidelity enzyme
(Agilent Technologies, Santa Clara, CA, USA). The prod-
ucts were then digested with DpnI (Roche, Indianapolis,
IN, USA) and 2 μl were used to transform the competent
TOP10 bacterial strain (Life Technologies). The presence
of the deletion was confirmed by Sanger sequencing. The






MYC silencing was generated infecting K562, LAMA-
84 and KCL-22 cells with lentiviral particles obtained
from modified FUGW lentiviral vectors: FUGW-MYC-
shRNA(shMYC) kindly provided from Dr. RN Eisenman
[44], FUGW-H1-scrambled control shRNA (shNC) was a
gift from Sally Temple [45] (Addgene plasmid # 40625;
Cambridge, MA, USA). Lentiviruses were packaged in
293-FT cells by co-transfecting the shRNA vectors with
the packaging pCMV-dR8.91 and VSVG plasmids using
jetPRIME Polyplus (Polyplus-transfection S.A, New-York,
NY, USA) following manufacturer recommendations.
Lentiviruses-infected cells were analyzed for GFP posi-
tivity with a a FACSAria flow cytometer (BD Bioscience,
San Jose, CA, USA) and FACS-sorted when infection
efficiency was lower than 85 %.
Generation of MYC and MAX expressing cell lines
MAX cDNA was obtained from total RNA of K562 cell
line. Two primers spanning the whole MAX coding
sequence (NM_145112.2) and introducing artificial
HindIII and EcoRI sites at the 5′ and 3′ ends of the coding
region were used for amplification and the PCR product
was cloned into the pCDNA3 vector. Sequences of the
primers were: MAX_Fw 5′AATAAAGCTTGAAATGAG
CGATAACGATGAC3′; Max_Rw 3′AATAGAATTCCCC
GAGTGGCTTAGCTGGCCT5′. pWZL_Blast_MYC vector
was a gift from William Hahn [46] (Addgene, plasmid #
10674). K562 cells were electroporated using a GenePulser
XCell (Bio-Rad, Hercules, CA) (270 V, 975 μF). Trans-
fected cells were selected with 5 μg/ml blasticidin and/
or 1 mg/ml geneticin.
Luciferase assay
293 cells were infected with the lentiviral vectors en-
coding either MYC-shRNA(shMYC) or the scrambled-
shRNA(shNC). RT-qPCR and Western Blot were used
to confirm MYC down-regulation. Infected 293 cells
were then co-transfected with pRL and pGL3/BCR
promoter constructs prepared as described in Marega
et al. [10] and luciferase activity was determined after
72 h using the Dual-Luciferase Reporter Assay
(Promega, Madison, WI, USA) and measured with
the 1450 Wallac MicroBeta®luminometer (PerkinElmer,
Waltham, Massachusetts, USA). All the experiments
were performed in triplicates.
Cell viability assay
Cell viability was monitored by CellTiter 96 AQ One
Solution Cell Proliferation Assay (Promega). The MTS
tetrazolium reagent was added to the cells after 24h,
48h, 72h and 96h from seeding. Absorbance was assayed
with a Wallac 1450 MicroBeta Trilux (PerkinElmer).
Cell cycle analysis
Cells were fixed in ethanol and stained with propidium-
iodide (Sigma-Aldrich). Flow cytometry was performed
on a Becton Dickinson FACSCalibur (Becton Dickinson
Immunocytometry Systems, Mountain view, CA, USA)
and data were analysed by FCS Express 4 Flow Research
Edition software.
Statistical analysis
All the statistical analyses (unpaired two-tailed T-test)
were performed by the GraphPad Prism (GraphPad, CA,
USA) statistical package.
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